Long-term use of 5α-reductase inhibitors and the risk of male breast cancer

• Published in: Cancer causes & control 2014-11, Vol.25 (11), p.1577-1582
• Main Authors: Duijnhoven, Ruben G., Straus, Sabine M. J. M., Souverein, Patrick C., de Boer, Anthonius, Bosch, J. L. H. Ruud, Hoes, Arno W., De Bruin, Marie L.
• Format: Article
• Language: English
• Subjects: 5-alpha Reductase Inhibitors - administration & dosage; 5-alpha Reductase Inhibitors - adverse effects; Aged; Aged, 80 and over; Biomedical and Life Sciences; Biomedicine; Body mass index; Breast cancer; Breast Neoplasms, Male - epidemiology; Breast Neoplasms, Male - etiology; BRIEF REPORT; Cancer; Cancer Research; Case-Control Studies; Dutasteride - administration & dosage; Dutasteride - adverse effects; Epidemiology; Finasteride - administration & dosage; Finasteride - adverse effects; General practice; Gynecomastia; Hematology; Humans; Lymphoma; Male; Male breast neoplasms; Medications; Middle Aged; Oncology; Prostatic hyperplasia; Prostatic Hyperplasia - drug therapy; Public Health; Risk Factors; United Kingdom - epidemiology
• ISSN: 0957-5243; 1573-7225
• DOI: 10.1007/s10552-014-0455-6

Background: The 5α-reductase inhibitors (5-ARI) finasteride and dutasteride are indicated for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia. Case reports have suggested that 5-ARIs increase the risk for male breast cancer, with no conclusive evidence. The objective of this study was to quantify the association between use of 5-ARIs and the risk for male breast cancer. Methods: A case–control study was conducted with data from the United Kingdom Clinical Practice Research Datalink database among all men aged 45 years and older in the period 1 January 1992 to 31 December 2011. Cases of men diagnosed with breast cancer were matched to up 10 controls on age and general practice. Crude and adjusted odds ratios were estimated for the risk of breast cancer associated with the use of 5-ARIs. Results: Three hundred and ninety-eight cases were identified and matched to 3,930 controls. Ever use of 5-ARIs was associated with an adjusted odds ratio for breast cancer of 1.08 (95 % CI 0.62–1.87) compared to non-users. Increasing cumulative duration of treatment showed no increasing risks: adjusted odds ratios for use for less than 280, for 280 to 1,036 and for more than 1,036 days were 1.21 (95 % CI 0.47–3.10), 0.94 (95 % CI 0.36–2.41) and 1.29 (95 % CI 0.54–3.08), respectively. Conclusions: In this study, there was no evidence of an association between short- or long-term treatment with 5-ARIs and the risk for breast cancer in older men.